Adaptin Bio, Inc.

APTN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023
Operating Activities
Net Income $-5.2M $-3.1M $-85.6K
Depreciation & Amortization
Depreciation
Amortization
Stock-Based Compensation $496.9K
Net Cash from Operating Activities $-4.8M $-649.3K $-81.0K
Investing Activities
Capital Expenditures
Business Acquisitions
Net Cash from Investing Activities
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $5.2M $678.6K $80.9K
Net Change in Cash
Free Cash Flow